// App-Quantinova.ai

1260 : Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Petra Muus

Principal Investigators

  • Alexander Roeth

  • M.O Elebute

  • Antonio M. Risitano

  • Hubert Schrezenmeier

  • Jaroslaw P. Maciejewski

  • Alvaro Urbano-Ispizua

  • Carlos Manuel de Castro III

  • Gerard Socie

  • Robert A. Brodsky

Medical Centers

  • Radboud University Medical Center, Njmegen, Netherlands

  • Royal Melbourne Hospital, Melbourne, Australia

  • Federico II University, Naples, Italy

  • University of Duisburg-Essen, Essen, Germany

  • Kings College Hospital London, Department of Haematological Medicine, London, United Kingdom

  • Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

  • Department of Hematology/Transplantation, Hopital Saint-Louis and Institut National de la Sante et de la Recherche Medicale INSERM, Paris, France

  • Grupo de Trabajo de HPN de la Sociedad Espanola de Hematologia y Hemoterapia, Barcelona, Spain

Locations

  • Italy

  • Netherlands

  • Germany

  • Spain

  • United Kingdom

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Alpha-thalassemia myelodysplasia syndrome

  • Renal insufficiency

  • Aplastic anemia

  • Venous thrombosis

  • Anemia

  • Sepsis

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Ciprofloxacin

  • ceftriaxone

  • Romiplostim

  • Eculizumab

  • Penicillin

  • Benzylpenicillin

  • vancomycin capsule

  • imipenem

  • Rocephin injectable vials

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved